Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Flexion’s Knee Pain Drug Gets FDA Approval

Divya Grover  |  October 9, 2017

(Reuters)—Flexion Therapeutics Inc. said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration.

The approval comes at a time when U.S. federal authorities are implementing a slew of measures to combat opioid abuse, with President Donald Trump in August declaring the opioid epidemic a national emergency.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The osteoarthritis drug, Zilretta (triamcinolone acetonide extended-release injectable suspension), will treat moderate to severe knee pain. It would be priced at about $500 per shot and launched in October, Flexion’s CEO Mike Clayman tells Reuters.

The market for osteoarthritis drugs is expected to increase from $1.6 billion in 2016 to $3.5 billion by 2026, according to GlobalData.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Zilretta … has the potential to be a gamechanger in osteoarthritis knee pain treatment,” Wells Fargo analyst David Maris says.

Zilretta could bag potential peak sales of more than $750 million, Northland Capital Markets analyst Carl Byrnes says.

Steroids move rapidly from joints into the blood elevating sugar levels in diabetic patients. Zilretta, however, is slowly released in the body and reaches the blood in much lower concentrations, preventing major changes in blood-glucose levels.

Development of rival drugs from Japan’s Seikagaku Corp and South Korea’s Kolon Life Science Inc. is underway.

Share: 

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:FDAFood and Drug Administrationknee painosteoarthritis (OA)triamcinolone acetonideU.S. Food and Drug AdministrationZilretta

Related Articles
    ah_designs / shutterstock.com

    The Perils of Pain Meds Revisited

    December 18, 2018

    More than 10 years ago, I wrote a commentary in The Rheumatologist, called “Perils of Pain Meds,” about the over-prescribing of opioid analgesics for common causes of chronic noncancer pain, which was a major contributor to the opioid epidemic.1 Since that time, although there has been a greater than 20% decrease in opioid prescribing, the…

    Pain Treatments Move Closer to U.S. Market

    October 18, 2017

    Two pain treatments, extended-release injectable suspension triamcinolone acetonide (Zilretta) and meloxicam, have seen movement at the U.S. Food and Drug Administration (FDA). In October, the agency approved Zilretta to treat osteoarthritis (OA) knee pain and accepted a new drug application for meloxicam to treat pain. FDA Approves Zilretta On Oct. 6, the FDA approved extended-release,…

    Exercise Therapy Recommended to Manage Knee Osteoarthritis

    July 12, 2016

    The benefits of exercise therapy for individuals with knee osteoarthritis (OA) are well known. The ACR strongly recommends both aquatic exercise and land-based aerobic and resistance exercise for managing knee OA.1 A recent Cochrane systematic review and meta-analysis concluded that high-quality evidence supports the use of exercise to reduce pain and improve physical function and…

    Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA

    October 15, 2018

    A recent study suggests Zilretta, an intra-articular injection for OA knee pain, may lower blood glucose levels in OA patients…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences